Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.

By Mario Peichev, A. Naiyer, D. Pereira, Zhen-ping Zhu, W. Lane, Mathew R. Williams, M. Oz, D. Hicklin, L. Witte, M. Moore and 1 more. Blood, 2000

2,462 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. (2007, background): “CD133 is expressed by normal tissue-resident as well as hematopoietic stem cells (Peichev et al., 2000; Uchida et al., 2000; Yin et al., 1997).”
CD133, a novel marker for human prostatic epithelial stem cells (2004, neutral): “1997), endothelial cells (Peichev et al., 2000), neurons and”
Origin of endothelial progenitors in human postnatal bone marrow. (2002, methodology): “Upon differentiation to mature endothelium, the AC133 receptor is quickly lost (1, 5).”
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models (2008, background): “Although the exact features of their phenotype remain controversial, the lineage-marker combination that is commonly used to identify circulating EPCs is CD133 + CD34 + VEGFR2 + (vascular endothelial growth factor receptor 2”
Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. (2002, background): “Our data show that MMP-9 mediated HSCs, CEPs (Peichev et al., 2000), and cardiac precursors (Orlic et al., 2001).”